Dementia and Movement Disorder Treatment Market: 45% of Growth to Originate from North America | By Drug Class and Geography - Forecast and Analysis 2022-2026

Download sample report to know Market Share, Size, Exact Growth Variance, and the Y-O-Y Growth Rate

Dementia and Movement Disorder Treatment Market 2022-2026: Segmentation

• Geography
• North America
• Europe
• Asia
• Rest of World (ROW)

45% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for the dementia and movement disorder treatment market in North America. Market growth in this region will be faster than the growth of the market in Rest of World (ROW). The growing prevalence of target diseases such as Alzheimer's disease and Parkinson's disease will facilitate the dementia and movement disorder treatment market growth in North America over the forecast period.

• Drug Class
• MAO Inhibitors
• Acetylcholinesterase Inhibitors
• Glutamate Inhibitors
• Others

The dementia and movement disorder treatment market share growth by the MAO inhibitors segment will be significant during the forecast period. Due to the high efficacy and specificity, MAO inhibitors are used as a monotherapy in early Parkinson's disease or as adjunctive therapy in patients suffering from motor-related symptoms of Parkinson's disease. Thus, the rising prevalence of Parkinson's disease and related disorders is expected to lead to an increase in the consumption of MAO inhibitors. This, in turn, will drive the dementia and movement disorder treatment market growth during the forecast period.

Download Our Sample Report to gain further insights on the market contribution & share of various segments & regions

Dementia and Movement Disorder Treatment Market 2022-2026: Driver

One of the key drivers supporting the dementia and movement disorder treatment market growth is the growing geriatric population. In 2020, regions such as Eastern and South-Eastern Asia were home to the largest number of the world geriatric population, with 260 million people falling into the age group of 65 years and above. According to the World Health Organization (WHO), in September 2021, around 55 million people had dementia globally. Out of these, over 60% were living in low- and middle-income countries. The geriatric population is increasing in low- and middle-income countries, particularly in Eastern and South-Eastern Asia. In view of this, the number of people with dementia is expected to rise to 78 million by 2030 and 139 million by 2050 globally. The increase in the geriatric population in nations worldwide will increase the risk of developing neurological disorders, including dementia, thereby increasing the demand for dementia drugs, thus driving the market growth during the forecast period.

Dementia and Movement Disorder Treatment Market 2022-2026: Challenge

One of the key factors hindering the dementia and movement disorder treatment market growth is the rise in the economic burden of neurological disorders. As per the CDC, Alzheimer's disease is one of the top ten leading causes of death in the US. Thus, there is a high requirement for treating Alzheimer's disease in the US. However, the growing treatment costs act as a challenge to patients in the US. A study titled The Economic Burden of Parkinson's Disease was conducted and published by the Michael J. Fox Foundation, along with national organizations in the US. The study estimated that the total cost of Parkinson's disease to individuals, families, and the US government is $51.9 billion annually. Thus, the economic burden of the disease is expected to increase with an increase in the geriatric population in the US, thereby making it a public healthcare concern and thereby hampering the dementia and movement disorder treatment market growth.

Download sample Report for insights on the drivers, trends, and challenges that will help companies evaluate and develop growth strategies for 2022-2026

Dementia and Movement Disorder Treatment Market 2022-2026: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our report covers the following areas:

• Dementia and Movement Disorder Treatment Market size
• Dementia and Movement Disorder Treatment Market trends
• Dementia and Movement Disorder Treatment Market analysis

Dementia and Movement Disorder Treatment Market 2022-2026: Vendor Analysis

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

• AbbVie Inc.
• Acorda Therapeutics Inc.
• Amneal Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• Biogen Inc.
• Eisai Co. Ltd.
• GlaxoSmithKline Plc
• H Lundbeck AS
• Johnson and Johnson
• Kyowa Kirin Co. Ltd.
• Lannett Co. Inc.
• Merck and Co. Inc.
• Neurocrine Biosciences Inc.
• Novartis AG
• Organon and Co.
• Orion Pharma Ltd.
• Otsuka Holdings Co. Ltd.
• Supernus Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.
• UCB SA
• Vertical Pharmaceuticals LLC

The dementia and movement disorder treatment market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Download Our Sample Report for more vendor insights with product offerings & news

Dementia and Movement Disorder Treatment Market 2022-2026: Key Highlights

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will assist dementia and movement disorder treatment market growth during the next five years
• Estimation of the dementia and movement disorder treatment market size and its contribution to the parent market
• Predictions on upcoming trends and changes in consumer behavior
• The growth of the dementia and movement disorder treatment market
• Analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of dementia and movement disorder treatment market vendors

Related Reports:

Neurodegenerative Diseases Therapeutics Market by Indication and Geography - Forecast and Analysis 2022-2026: Based on Technavio's market sizing methodology, the neurodegenerative diseases therapeutics market size is predicted to surge by USD 19.74 billion from 2021 to 2026 at a CAGR of 7.98%. To get more exclusive research insights: Download Our Sample Report

Brain Health Supplements Market by Distribution Channel and Geography - Forecast and Analysis 2022-2026: The brain health supplements market share is expected to increase by USD 3.81 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.34%. To get more exclusive research insights: Download Our Sample Report

Table of Contents:

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Drug Class
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
• Exhibit 17: Five forces analysis - Comparison between2021 and 2026

• 4.2 Bargaining power of buyers
• Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026

• 4.3 Bargaining power of suppliers
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Drug Class

• 5.1 Market segments
• Exhibit 24: Chart on Drug Class - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Drug Class - Market share 2021-2026 (%)

• 5.2 Comparison by Drug Class
• Exhibit 26: Chart on Comparison by Drug Class
• Exhibit 27: Data Table on Comparison by Drug Class

• 5.3 MAO inhibitors - Market size and forecast 2021-2026
• Exhibit 28: Chart on MAO inhibitors - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on MAO inhibitors - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on MAO inhibitors - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on MAO inhibitors - Year-over-year growth 2021-2026 (%)

• 5.4 Acetylcholinesterase inhibitors - Market size and forecast 2021-2026
• Exhibit 32: Chart on Acetylcholinesterase inhibitors - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Acetylcholinesterase inhibitors - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Acetylcholinesterase inhibitors - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Acetylcholinesterase inhibitors - Year-over-year growth 2021-2026 (%)

• 5.5 Glutamate inhibitors - Market size and forecast 2021-2026
• Exhibit 36: Chart on Glutamate inhibitors - Market size and forecast 2021-2026 ($ million)
• Exhibit 37: Data Table on Glutamate inhibitors - Market size and forecast 2021-2026 ($ million)
• Exhibit 38: Chart on Glutamate inhibitors - Year-over-year growth 2021-2026 (%)
• Exhibit 39: Data Table on Glutamate inhibitors - Year-over-year growth 2021-2026 (%)

• 5.6 Others - Market size and forecast 2021-2026
• Exhibit 40: Chart on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 41: Data Table on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 42: Chart on Others - Year-over-year growth 2021-2026 (%)
• Exhibit 43: Data Table on Others - Year-over-year growth 2021-2026 (%)

• 5.7 Market opportunity by Drug Class
• Exhibit 44: Market opportunity by Drug Class ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview
• Exhibit 45: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation
• Exhibit 46: Chart on Market share by geography 2021-2026 (%)
• Exhibit 47: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison
• Exhibit 48: Chart on Geographic comparison
• Exhibit 49: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 50: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 54: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 58: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 62: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 66: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Germany - Market size and forecast 2021-2026
• Exhibit 70: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 7.9 UK - Market size and forecast 2021-2026
• Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.10 Canada - Market size and forecast 2021-2026
• Exhibit 78: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 79: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 80: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 81: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.11 France - Market size and forecast 2021-2026
• Exhibit 82: Chart on France - Market size and forecast 2021-2026 ($ million)
• Exhibit 83: Data Table on France - Market size and forecast 2021-2026 ($ million)
• Exhibit 84: Chart on France - Year-over-year growth 2021-2026 (%)
• Exhibit 85: Data Table on France - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography
• Exhibit 86: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges
• Exhibit 87: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape
• Exhibit 88: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption
• Exhibit 89: Overview on factors of disruption

• 9.4 Industry risks
• Exhibit 90: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered
• Exhibit 91: Vendors covered

• 10.2 Market positioning of vendors
• Exhibit 92: Matrix on vendor position and classification

• 10.3 AbbVie Inc.
• Exhibit 93: AbbVie Inc. - Overview
• Exhibit 94: AbbVie Inc. - Product / Service
• Exhibit 95: AbbVie Inc. - Key offerings

• 10.4 Biogen Inc.
• Exhibit 96: Biogen Inc. - Overview
• Exhibit 97: Biogen Inc. - Product / Service
• Exhibit 98: Biogen Inc. - Key offerings

• 10.5 Eisai Co. Ltd.
• Exhibit 99: Eisai Co. Ltd. - Overview
• Exhibit 100: Eisai Co. Ltd. - Business segments
• Exhibit 101: Eisai Co. Ltd. - Key offerings
• Exhibit 102: Eisai Co. Ltd. - Segment focus

• 10.6 H Lundbeck AS
• Exhibit 103: H Lundbeck AS - Overview
• Exhibit 104: H Lundbeck AS - Product / Service
• Exhibit 105: H Lundbeck AS - Key offerings

• 10.7 Johnson and Johnson
• Exhibit 106: Johnson and Johnson - Overview
• Exhibit 107: Johnson and Johnson - Business segments
• Exhibit 108: Johnson and Johnson - Key news
• Exhibit 109: Johnson and Johnson - Key offerings
• Exhibit 110: Johnson and Johnson - Segment focus

• 10.8 Merck and Co. Inc.
• Exhibit 111: Merck and Co. Inc. - Overview
• Exhibit 112: Merck and Co. Inc. - Business segments
• Exhibit 113: Merck and Co. Inc. - Key news
• Exhibit 114: Merck and Co. Inc. - Key offerings
• Exhibit 115: Merck and Co. Inc. - Segment focus

• 10.9 Novartis AG
• Exhibit 116: Novartis AG - Overview
• Exhibit 117: Novartis AG - Business segments
• Exhibit 118: Novartis AG - Key offerings
• Exhibit 119: Novartis AG - Segment focus

• 10.10 Otsuka Holdings Co. Ltd.
• Exhibit 120: Otsuka Holdings Co. Ltd. - Overview
• Exhibit 121: Otsuka Holdings Co. Ltd. - Business segments
• Exhibit 122: Otsuka Holdings Co. Ltd. - Key offerings
• Exhibit 123: Otsuka Holdings Co. Ltd. - Segment focus

• 10.11 Teva Pharmaceutical Industries Ltd.
• Exhibit 124: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 125: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 126: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 127: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 128: Teva Pharmaceutical Industries Ltd. - Segment focus

• 10.12 UCB SA
• Exhibit 129: UCB SA - Overview
• Exhibit 130: UCB SA - Product / Service
• Exhibit 131: UCB SA - Key offerings

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist
• Exhibit 132: Inclusions checklist
• Exhibit 133: Exclusions checklist

• 11.3 Currency conversion rates for US$
• Exhibit 134: Currency conversion rates for US$

• 11.4 Research methodology
• Exhibit 135: Research methodology
• Exhibit 136: Validation techniques employed for market sizing
• Exhibit 137: Information sources

• 11.5 List of abbreviations
• Exhibit 138: List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio